Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Abnormal accumulation of β-amyloid (Aβ) in Alzheimer's disease (AD) is associated with prominent brain inflammation. Whereas earlier studies concluded that this inflammation is detrimental, more recent animal data suggest that at least some inflammatory processes may be beneficial and promote Aβ clearance. Consistent with these observations, overproduction of transforming growth factor (TGF)-β1 resulted in a vigorous microglial activation that was accompanied by at least a 50% reduction in Aβ accumulation in human amyloid precursor protein (hAPP) transgenic mice. In a search for inflammatory mediators associated with this reduced pathology, we found that brain levels of C3, the central component of complement and a key inflammatory protein activated in AD, were markedly higher in hAPP/TGF-β1 mice than in hAPP mice. To assess the importance of complement in the pathogenesis of AD-like disease in mice, we inhibited C3 activation by expressing soluble complement receptor-related protein y (sCrry), a complement inhibitor, in the brains of hAPP mice. Aβ deposition was 2- to 3-fold higher in 1-year-old hAPP/sCrry mice than in age-matched hAPP mice and was accompanied by a prominent accumulation of degenerating neurons. These results indicate that complement activation products can protect against Aβ-induced neurotoxicity and may reduce the accumulation or promote the clearance of amyloid and degenerating neurons. These findings provide evidence for a role of complement and innate immune responses in AD-like disease in mice and support the concept that certain inflammatory defense mechanisms in the brain may be beneficial in neurodegenerative disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“other studies have reported that inhibition of different components of complement impaired Aβ phagocytosis, resulting in elevated synapse loss.”
From Microglia in Alzheimer's disease (2017) · cites this paper as [122]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The deficiency of complement factors such as C1q, C3, C3ar1, C5aR, and Cd59, has exacerbated neuropathology in some studies [84–86] and reduced neuropathology in others [87–89].”
From Age, sex and Alzheimer’s disease: a longitudinal study of 3xTg-AD mice reveals sex-specific disease trajectories and inflammatory responses mirrored in postmortem brains from Alzheimer’s patients (2024) · cites this paper as [85]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In the same studies, complement blockade was associated with increased neurodegeneration.”
From Microglia in Alzheimer's disease (2017) · cites this paper as [122]
The cited source says what the claim attributes to it.
In the citing paper
“C3 inhibition enhanced plaque deposition and promoted neurodegeneration in J20 hAPP mice either by over-expression of sCrry (22) or genetic deletion of C3 (21).”
From Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice (2017) · cites this paper as [22]
The cited source says what the claim attributes to it.
In the citing paper
“Further, studies manipulating the complement system have yielded mixed results.”
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Self-citationImmunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Cellular Scaling Rules for the Brains of Marsupials: Not as “Primitive” as Expected
Dos Santos, S. E., Porfirio, J., da Cunha, F. B., Manger, P. R., Tavares, W., Pessoa, L., Raghanti, M. A., Sherwood, C. C., & Herculano-Houzel, S. (2017) · Brain, Behavior and Evolution · doi:10.1159/000452856 · Cited by 2,642
NeuN, a neuronal specific nuclear protein in vertebratesxs
Mullen, R. J., Buck, C. R., & Smith, A. M. (1992) · Development · doi:10.1242/dev.116.1.201 · Cited by 2,351
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012
Mucke, L., Masliah, E., Yu, G.-Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., & McConlogue, L. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04050.2000 · Cited by 1,856
Self-citationAβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease
Morgan, D., Diamond, D. M., Gottschall, P. E., Ugen, K. E., Dickey, C., Hardy, J., Duff, K., Jantzen, P., DiCarlo, G., Wilcock, D., et al. (2000) · Nature · doi:10.1038/35050116 · Cited by 1,498
Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies
Botto, M., Dell' Agnola, C., Bygrave, A. E., Thompson, E. M., Cook, H. T., Petry, F., Loos, M., Pandolfi, P. P., & Walport, M. J. (1998) · Nature Genetics · doi:10.1038/ng0598-56 · Cited by 1,434
Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., Chishti, M. A., Horne, P., Heslin, D., French, J., et al. (2000) · Nature · doi:10.1038/35050110 · Cited by 1,431
Inflammation in Neurodegenerative Disease—A Double-Edged Sword
Wyss-Coray, T., & Mucke, L. (2002) · Neuron · doi:10.1016/s0896-6273(02)00794-8 · Cited by 1,235
Self-citation
Research works printed but not linked: 4
- Wyss-Coray, T. & Mucke, L. (2002) Neuron, in press. [DOI] [PubMed]
- Terry R. D., Masliah, E. & Hansen, L. A. (1994) in Alzheimer Disease, eds. Terry, R. D., Katzman, R. & Bick, K. L. (Raven, New York), pp. 179–196.
- Frautschy S. A., Cole, G. M. & Baird, A. (1992) Am. J. Pathol. 140, 1389-1399. [PMC free article] [PubMed] [Google Scholar]
- Holers V. M. (1996) in Clinical Immunology: Principles and Practice, ed. Rich, R. R. (Mosby, St. Louis), pp. 363–391.
Cited by
Items 201–300 of 466
A nasal proteosome adjuvant activates microglia and prevents amyloid deposition
Frenkel, D., Puckett, L., Petrovic, S., Xia, W., Chen, G., Vega, J., Dembinsky‐Vaknin, A., Shen, J., Plante, M., Burt, D. S., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21340 · Cited by 56
“and insoluble A (1-40) and (1-42) by 56 and 79%, respectively, in the brain (Fig 2 and Table 2).”
BackgroundInfluentialOhmi, Y., Ohkawa, Y., Yamauchi, Y., Tajima, O., Furukawa, K., & Furukawa, K. (2012) · Neurochemical Research · doi:10.1007/s11064-012-0764-7 · Cited by 84
Nanomedicine-based immunotherapy for central nervous system disorders
Hanif, S., Muhammad, P., Chesworth, R., Rehman, F. U., Qian, R., Zheng, M., & Shi, B. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0429-z · Cited by 75
Alexander, J. J., Bao, L., Jacob, A., Kraus, D. M., Holers, V. M., & Quigg, R. J. (2003) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2003.09.005 · Cited by 68
“The complement cascade is involved in the development of brain pathology in diseases such as SLE and injury [1].”
BackgroundSelf-citationLv, Z., Chen, L., Chen, P., Peng, H., Rong, Y., Hong, W., Zhou, Q., Li, N., Li, B., Paolicelli, R. C., et al. (2024) · Neuron · doi:10.1016/j.neuron.2023.12.003 · Cited by 69
Ricciarelli, R., d'Abramo, C., Zingg, J.-M., Giliberto, L., Markesbery, W., Azzi, A., Marinari, U. M., Pronzato, M. A., & Tabaton, M. (2004) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2004.01.007 · Cited by 66
Kauwe, J. S. K., Cruchaga, C., Karch, C. M., Sadler, B., Lee, M., Mayo, K., Latu, W., Su'a, M., Fagan, A. M., Holtzman, D. M., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0015918 · Cited by 66
Bohm, C., Chen, F., Sevalle, J., Qamar, S., Dodd, R., Li, Y., Schmitt-Ulms, G., Fraser, P. E., & St George-Hyslop, P. H. (2015) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2015.02.016 · Cited by 63
“Similarly, both coding (rare sequence variants and a common in frame insertion) and non-coding sequence variants in the complement receptor 1 (CR1) have been associated with late-onset AD (Hazrati et al., 2012; Jun et al., 2010; Naj et al., 2011; Wyss-Coray et al., 2002).”
BackgroundInsights into the Pathogenesis of Hydrocephalus from Transgenic and Experimental Animal Models
Crews, L. A., Wyss‐Coray, T., & Masliah, E. (2004) · Brain Pathology · doi:10.1111/j.1750-3639.2004.tb00070.x · Cited by 66
“Chronic disruption of the perivascular ECM in these tg mice also results in progressive accumulation of amyloid-like proteins that leads to congophilic (amyloid) angiopathy (Figure 3H) similar to that observed in Alzheimer disease and other neurodegenerative dementing disorders (48).”
ResultSelf-citationWirz, K. T. S., Bossers, K., Stargardt, A., Kamphuis, W., Swaab, D. F., Hol, E. M., & Verhaagen, J. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.11.008 · Cited by 65
Emerging perspectives on mitochondrial dysfunction and inflammation in Alzheimer’s disease
Yoo, S., Park, J., Kim, S., & Jung, Y. (2020) · BMB Reports · doi:10.5483/bmbrep.2020.53.1.274 · Cited by 65
“deposition and the number of degenerating neurons (16).”
BackgroundTargeting Microglia-Synapse Interactions in Alzheimer’s Disease
Piccioni, G., Mango, D., Saidi, A., Corbo, M., & Nisticò, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052342 · Cited by 63
“More recent studies have suggested that a sustained immune response in the brain facilitates and aggravates both Aβ and NFT pathologies and neurodegeneration [26,27].”
BackgroundFas Ligand-Mediated Apoptosis in Degenerative Disorders of the Brain
Ethell, D. W., & Buhler, L. A. (2003) · Journal of Clinical Immunology · doi:10.1023/b:joci.0000010420.96419.a8 · Cited by 80
“Inhibition of complement by overexpression of complement receptor related protein y (Crry) caused a 2–3-fold increase in Aβ deposition in a hAPP mouse model for AD (74).”
BackgroundZetzsche, T., Rujescu, D., Hardy, J., & Hampel, H. (2010) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.10.48 · Cited by 60
Beta-Amyloid and Tau-Protein: Structure, Interaction, and Prion-Like Properties
Tatarnikova, O. G., Орлов, М. А., & Bobkova, N. V. (2015) · Biochemistry (Moscow) · doi:10.1134/s000629791513012x · Cited by 72
“In this way, coding (uncommon versions of the sequence itself and common insertions in it) and noncoding parts of the gene encoding receptor 1 of the complement system (CR1) are connected with the development of late-stage AD [43, 47-49].”
BackgroundThe Role of Glial Cells in Synaptic Dysfunction: Insights into Alzheimer's Disease Mechanisms
Yu, Y., Chen, R., Mao, K., Deng, M., & Li, Z. (2023) · Aging and Disease · doi:10.14336/ad.2023.0718 · Cited by 66
The complement system in central nervous system diseases
Rus, H., Cudrici, C., David, S., & Niculescu, F. (2006) · Autoimmunity · doi:10.1080/08916930600739605 · Cited by 61
“[83] Wyss-Coray T, Yan F, Lin AH-T, Lambris JD, Alexander JJ, Quigg RJ, et al.”
BackgroundWoodling, N. S., & Andreasson, K. I. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00016 · Cited by 63
Molecular basis for detection of invading pathogens in the brain
Falsig, J., van Beek, J., Hermann, C., & Leist, M. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21590 · Cited by 62
“Transgenic hAPP mice coexpressing a soluble form of the complement inhibitor Crry under the glial fibrillary acidic protein promoter displayed increased b-amyloid deposits and more prominent neurodegeneration than what is found in age-matched mice (Wyss-Coray et al., 2002).”
BackgroundImplications of heparan sulfate and heparanase in neuroinflammation
Zhang, X., Wang, B., & Li, J.-P. (2014) · Matrix Biology · doi:10.1016/j.matbio.2013.12.009 · Cited by 59
“…that macrophages differentiated from blood-borne monocytes infiltrated into brain parenchyma also play important roles in neuroinflammation (Wyss-Coray et al., 2002; Frank-Cannon et al., 2009; Rezai-Zadeh et al., 2009) Although physiological surveillance of the brain by peripheral…”
BackgroundThe Role of the Classical Complement Cascade in Synapse Loss During Development and Glaucoma
Rosen, A. M., & Stevens, B. (2010) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4419-5635-4_6 · Cited by 60
The complement system in neurodegenerative diseases
Nimmo, J., Byrne, R. A. J., Daskoulidou, N., Watkins, L. M., Carpanini, S. M., Zelek, W. M., & Morgan, B. P. (2024) · Clinical Science · doi:10.1042/cs20230513 · Cited by 61
“Moreover, 1-year-old APP mice expressing the C3 inhibitor soluble complement receptor-related protein y (sCrry) exhibited a 2-to 3-fold higher amyloid beta deposition accompanied by accumulation of degenerating neurons when compared with age-matched APP mice [77].”
ResultDysfunction of TGF-β signaling in Alzheimer’s disease
Das, P., & Golde, T. (2006) · Journal of Clinical Investigation · doi:10.1172/jci30284 · Cited by 58
Olgiati, P., Politis, A. M., Papadimitriou, G. N., De Ronchi, D., & Serretti, A. (2011) · International Journal of Alzheimer’s Disease · doi:10.4061/2011/832379 · Cited by 57
“Notably, complement inhibition was shown to reduce the clearance of beta amyloid in animal models [50].”
BackgroundLee, D. C., Rizer, J., Hunt, J. B., Selenica, M. ‐. B., Gordon, M. N., & Morgan, D. (2013) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12002 · Cited by 57
Rasmussen, K. L., Nordestgaard, B. G., Frikke‐Schmidt, R., & Nielsen, S. F. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.07.223 · Cited by 53
“Finally, deficiency of complement C3 (by C32/2 knockout) or a relative inhibition of complement C3 was associated with AD–related measurements in mice models [11,12].”
BackgroundResultInfluentialMalm, T. M., Magga, J., Kuh, G. F., Vatanen, T., Koistinaho, M., & Koistinaho, J. (2008) · Glia · doi:10.1002/glia.20726 · Cited by 52
“…and Lue, 2001), others have shown that activation of microglial/monocytic cells is beneficial as it may facilitate the clearance of Ab from the brain and participate in the regeneration of CNS after injury (Bard et al., 2000; Schenk et al., 1999; Wyss-Coray et al., 2001; Wyss-Coray et al., 2002).”
BackgroundMechanistic role of boswellic acids in Alzheimer’s disease: Emphasis on anti-inflammatory properties
Siddiqui, A., Shah, Z., Jahan, R. N., Othman, I., & Kumari, Y. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112250 · Cited by 59
Cunningham, C., Wilcockson, D. C., Boche, D., & Perry, V. H. (2005) · Journal of Virology · doi:10.1128/jvi.79.8.5174-5184.2005 · Cited by 53
“In a transgenic mouse model of AD, the inhibition of C3 caused a substantial increase in amyloid deposition and overt neurodegeneration (56).”
Neuropeptides in Alzheimer’s Disease: An Update
Petrella, C., Di Certo, M. G., Barbato, C., Gabanella, F., Ralli, M., Greco, A., Possenti, R., & Severini, C. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190503152555 · Cited by 53
Morgan, B. P., Gommerman, J. L., & Ramaglia, V. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.600656 · Cited by 60
“For example, human amyloid precursor protein (hAPP) transgenic mice deficient in C3 or overexpressing the C3 convertase inhibitor complement receptor 1-related protein y (Crry), showed greater amyloid accumulation and greater cognitive deficits than control mice, suggesting a protective role for C3 activation (Wyss-Co…”
BackgroundComplement receptor 1 polymorphisms and risk of late-onset Alzheimer's disease
Zhang, Q., Yu, J., Zhu, Q.-X., Zhang, W., Wu, Z., Miao, D., & Tan, L. (2010) · Brain Research · doi:10.1016/j.brainres.2010.06.018 · Cited by 58
“On the contrary, inhibiting expression of C3 convertase leads to increased Aβ deposition and neurodegeneration (Wyss-Coray et al., 2002).”
The role of the complement system in Multiple Sclerosis: A review
Saez-Calveras, N., & Stüve, O. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.970486 · Cited by 57
Xu, Q., Cao, S., Rajapakse, S., & Matsubara, J. A. (2018) · Lipids in Health and Disease · doi:10.1186/s12944-017-0647-7 · Cited by 54
“Without complement activation, AD mice displayed higher Aβ deposition and more severe neurodegeneration when compared to mice of the same age [76].”
BackgroundHashiguchi, D., Campos, H. C., Wuo‐Silva, R., Faber, J., da Silva, S. G., Ribeiro, A. A. C. M., Arida, R. M., & Longo, B. M. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-190729 · Cited by 59
“Interestingly, Wyss-Coray et al. [47, 48] investigated the role of the complement system in the development of AD pathology in transgenic mice (hAPP).”
Neuroinflammation is increased in the parietal cortex of atypical Alzheimer’s disease
Boon, B. D. C., Hoozemans, J. J. M., Lopuhaä, B., Eigenhuis, K. N., Scheltens, P., Kamphorst, W., Rozemuller, A. J. M., & Bouwman, F. H. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1180-y · Cited by 48
“Most likely, the amyloid structure of fibrillar plaques favors a strong binding and activation of complement factors, which in turn could act as opsonins for phagocytosis carried out by microglia [17, 40, 41].”
BackgroundInduction of complement proteins in a mouse model for cerebral microvascular Aβ deposition
Fan, R., DeFilippis, K., & Van Nostrand, W. E. (2007) · Journal of Neuroinflammation · doi:10.1186/1742-2094-4-22 · Cited by 47
“In addition to the well-studied pathogen elimination by complement activation, amyloid clearance may be promoted by C1q binding to fibrillar amyloid deposits, and generation of an opsonin, the C3b fragment [15,25].”
BackgroundNeuroprotection from Complement‐Mediated Inflammatory Damage
Kulkarni, A. P., Kellaway, L. A., Lahiri, D. K., & Kotwal, G. J. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1332.010 · Cited by 56
Implication of common and disease specific variants in CLU, CR1, and PICALM
Ferrari, R., Moreno, J. H., Minhajuddin, A., O’Bryant, S. E., Reisch, J., Barber, R. C., & Momeni, P. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.01.110 · Cited by 53
Role of Nanomedicine-Based Therapeutics in the Treatment of CNS Disorders
Guo, Z.-H., Khattak, S., Rauf, M. A., Ansari, M. A., Alomary, M. N., Razak, S., Yang, C., Wu, D., & Ji, X. (2023) · Molecules · doi:10.3390/molecules28031283 · Cited by 60
Immunity and Alzheimer's disease: immunological perspectives on the development of novel therapies
Liu, Y.-H., Zeng, F., Wang, Y., Zhou, H., Giunta, B. N., Tan, J., & Wang, Y. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.07.020 · Cited by 49
Targeting Glial Cells to Elucidate the Pathogenesis of Huntington’s Disease
Hsiao, H., & Chern, Y. (2010) · Molecular Neurobiology · doi:10.1007/s12035-009-8097-5 · Cited by 54
“[ 72 ]. Activated microglia are associated with the products of complement activation and the membrane attack complex (MAC) on amyloid plaques and degenerating neurons [70, 71].”
BackgroundMcFarland, K. N., & Chakrabarty, P. (2022) · Neurotherapeutics · doi:10.1007/s13311-021-01179-3 · Cited by 48
“J20 x sCrry 10-12 mo ↑ Aβ ↓ hippocampus neuron [234]”
Wright, A. L., Konen, L. M., Mockett, B. G., Morris, G. P., Singh, A., Burbano, L. E., Milham, L. T., Hoang, M., Zinn, R., Chesworth, R., et al. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00632-5 · Cited by 50
“We also observed significantly reduced dendritic spine density and dendritic arborisation in J20 mice, compared with littermate controls [67, 93–98].”
ResultCSF complement 3 and factor H are staging biomarkers in Alzheimer’s disease
Initiative, F. T. A. D. N.-I., Hu, W. T., Watts, K. D., Tailor, P., Nguyen, T. P., Howell, J. C., Lee, R. C., Seyfried, N. T., Gearing, M., Hales, C. M., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0277-8 · Cited by 45
“Earlier data showed that C3 deactivation enhanced AD pathology in transgenic mice [32], and more recent data showed that acetylcholine enhances C3 activation in astrocytes in vitro [33].”
BackgroundNeuroinflammation in Alzheimer's disease and beneficial action of luteolin
Delgado, A., Cholevas, C., & Theoharides, T. C. (2021) · BioFactors · doi:10.1002/biof.1714 · Cited by 48
Brenner, T., Nizri, E., Irony-Tur-Sinai, M., Hamra‐Amitay, Y., & Wirguin, I. (2008) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2008.05.022 · Cited by 49
“Further along this line, it was also found that mice deficient in complement activity were affected to a greater extent by amyloid deposits, implicating the beneficial activity of the innate immune system (Wyss-Coray et al., 2002).”
BackgroundThe complement system in the peripheral nerve: Friend or foe?
Ramaglia, V., Daha, M. R., & Baas, F. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2008.06.018 · Cited by 49
Zabel, M., Schrag, M., Crofton, A., Tung, S., Beaufond, P., Van Ornam, J., DiNinni, A., Vinters, H. V., Coppola, G., & Kirsch, W. M. (2013) · Brain Pathology · doi:10.1111/bpa.12005 · Cited by 46
“Blocking the complement cascade at C3 is thought to result in increased AD pathology, neurodegeneration and an altered microglial phenotype (24, 48).”
BackgroundAlzheimer's Disease: Another Target for Heparin Therapy
Bergamaschini, L., Rossi, E., Vergani, C., & De Simoni, M. G. (2009) · The Scientific World JOURNAL · doi:10.1100/tsw.2009.100 · Cited by 47
“In transgenic animals, complement inhibition leads to increased AD, whereas increased C3 production reduces Aβ deposition[162].”
BackgroundDepboylu, C., Schorlemmer, K., Klietz, M., Oertel, W. H., Weihe, E., Höglinger, G. U., & Schäfer, M. K.-H. (2011) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2011.05.006 · Cited by 47
“In a mouse model of Alzheimer disease inhibition of complement C3 activation resulted in increased neurodegeneration and plaque formation (Wyss-Coray et al., 2002).”
BackgroundBritschgi, M., Takeda-Uchimura, Y., Rockenstein, E., Johns, H., Masliah, E., & Wyss-Coray, T. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-220 · Cited by 45
“For instance, overexpression of sCrry or ablating C3 in APP transgenic mouse models of AD accelerated formation of amyloid-β plaques and neurodegeneration [20,21].”
BackgroundSelf-citationInflammation takes on Alzheimer disease
Golde, T. E. (2002) · Nature Medicine · doi:10.1038/nm0902-936 · Cited by 45
“provide evidence that at least one arm of the inflammatory response may be protective against A”
Systemic inflammatory markers in ageing, Alzheimer's disease and other dementias
Cai, H., Zhao, T., Pang, Y., Fu, X., Ren, Z., Quan, S., & Jia, L. (2024) · Brain · doi:10.1093/brain/awae230 · Cited by 47
The role of complement in neurological and neuropsychiatric diseases
Morgan, B. P. (2015) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2015.1074039 · Cited by 44
“Deficiency of C1q reduced immunopathology suggesting a role for CP activation [47], while either C3 inhibition or C3 deficiency caused increased pathology [48,49].”
BackgroundAlzheimer’s disease beyond APOE
van Es, M. A., & van den Berg, L. H. (2009) · Nature Genetics · doi:10.1038/ng1009-1047 · Cited by 49
Bertram, L., & Tanzi, R. E. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.213 · Cited by 48
C3aR inhibition reduces neurodegeneration in experimental lupus
Jacob, A., Bao, L., Brorson, J., Quigg, R., & Alexander, J. (2010) · Lupus · doi:10.1177/0961203309348978 · Cited by 44
Self-citationLipotoxicity, neuroinflammation, glial cells and oestrogenic compounds
Hidalgo‐Lanussa, O., Báez-Jurado, E., Echeverría, V., Ashraf, G. M., Sahebkar, A., García‐Segura, L. M., Melcangi, R. C., & Barreto, G. E. (2019) · Journal of Neuroendocrinology · doi:10.1111/jne.12776 · Cited by 48
Neuroinflammation in Alzheimer’s Disease: Microglia, Molecular Participants and Therapeutic Choices
Wang, H., Shen, Y., Chuang, H., Chiu, C., Ye, Y., & Zhao, L. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190503151648 · Cited by 41
The role of the complement system in CNS inflammatory diseases
Stahel, P. F., & Barnum, S. R. (2006) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2.3.445 · Cited by 44
Barber, A. J., del Genio, C. L., Swain, A. B., Pizzi, E. M., Watson, S. C., Tapiavala, V. N., Zanazzi, G. J., & Gaur, A. B. (2024) · Alzheimer's Research & Therapy · doi:10.1186/s13195-024-01492-x · Cited by 41
Shie, F.-S., Nivison, M., Hsu, P.-C., & Montine, T. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709787458399 · Cited by 41
“In fact, double transgenic mice that overexpress an AD-causing mutant form of human APP as well as a natural inhibitor of complement C3 suggest that the innate immune response in AD may be beneficial in part by enhancing clearance of Aβ peptides from plaques through phagocytosis [54].”
BackgroundComplement receptor 1 is expressed on brain cells and in the human brain
Daskoulidou, N., Shaw, B., Torvell, M., Watkins, L., Cope, E. L., Carpanini, S. M., Allen, N. D., & Morgan, B. P. (2023) · Glia · doi:10.1002/glia.24355 · Cited by 40
“Data from animal models have implicated complement in amyloid clearance and in synapse loss (Maier et al., 2008; Shi et al., 2017; Wyss-Coray et al., 2002); notably, our recent study demonstrated that MAC formation is an important driver of synapse loss in AD models (Carpanini et al., 2022).”
ResultZhang, S.-S., Gao, Z., Feng, L., & Li, M. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s483412 · Cited by 40
“Conversely, research by Wyss-Coray et al 150 suggested that increased C3 expression may mitigate Aβ-induced neurotoxicity by either reducing Aβ production or enhancing its clearance.”
BackgroundCR1 genotype is associated with entorhinal cortex volume in young healthy adults
Bralten, J., Franke, B., Vásquez, A. A., Heister, A. J. G. A. M., Brunner, H. G., Fernández, G., & Rijpkema, M. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.05.017 · Cited by 44
Cochlear Immune Response in Presbyacusis: a Focus on Dysregulation of Macrophage Activity
Noble, K. V., Brown, L. N., Elvis, P. R., & Lang, H. (2021) · Journal of the Association for Research in Otolaryngology · doi:10.1007/s10162-021-00819-x · Cited by 44
Staging anti-inflammatory therapy in Alzheimer’s disease
Lichtenstein, M. P. (2010) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2010.00142 · Cited by 39
“, 2008), or the component system element C3 (Wyss-Coray et al., 2002).”
Transgenic models for cytokine-induced neurological disease
Campbell, I. L., Hofer, M. J., & Pagenstecher, A. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.10.004 · Cited by 43
“The mechanism responsible for the clearance of the amyloid plaques from hAPP-TGF-β1 transgenic mice appears to involve an innate immune response with activation of plaque associated microglia and complement-mediated phagocytosis of amyloid [178,179].”
Complement C1q expression induced by Aβ in rat hippocampal organotypic slice cultures
Fan, R., & Tenner, A. J. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2003.09.023 · Cited by 34
Is there a future for vaccination as a treatment for Alzheimer's disease?
McGeer, P. L., & McGeer, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00157-4 · Cited by 40
HSV amplicon-mediated Aβ vaccination in Tg2576 mice: differential antigen-specific immune responses
Bowers, W. J., Mastrangelo, M. A., Stanley, H. A., Casey, A. E., Milo, L. J., & Federoff, H. J. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.04.006 · Cited by 41
“In fact, amyloidogenic mice devoid of the complement component C3 exhibit markedly enhanced neurodegeneration and amyloid deposition, supporting an important role of complement activation and innate immune responses in protection from A -mediated neurotoxicity [65].”
BackgroundLeukocyte Telomere Length in Alzheimer’s Disease Patients with a Different Rate of Progression
Tedone, E., Arosio, B., Colombo, F., Ferri, E., Asselineau, D., Piette, F., Gussago, C., Belmin, J., Pariel, S., Benlhassan, K., et al. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-142808 · Cited by 36
“Inflammation is considered to be involved in AD etiopathogenesis through effects on neuronal homeostasis and immune response [54–58].”
BackgroundSokolova, D., Childs, T., & Hong, S. Y. (2021) · Faculty Reviews · doi:10.12703/r/10-19 · Cited by 39
Choucair-Jaafar, N., Laporte, V., Levy, R., Poindron, P., Lombard, Y., & Gies, J.-P. (2011) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.2010.00811.x · Cited by 35
CLU, CR1 and PICALM genes associate with Alzheimer's-related senile plaques
Kok, E. H., Luoto, T., Haikonen, S., Goebeler, S., Haapasalo, H., & Karhunen, P. J. (2011) · Alzheimer's Research & Therapy · doi:10.1186/alzrt71 · Cited by 35
“We hypothesised that the three other SNPs (CLU, CR1 and PICALM) would also associate with SP, as they are involved in AD pathways and most likely would be associated with the development of brain lesions [24-34].”
BackgroundNovel approaches for immunotherapeutic intervention in Alzheimer's disease
Vasilevko, V., & Cribbs, D. H. (2006) · Neurochemistry International · doi:10.1016/j.neuint.2006.03.019 · Cited by 39
Fu, H., Liu, B., Li, L., & Lemere, C. A. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.07.020 · Cited by 37
“Many receptors have been found to mediate the uptake and clearance of fAβ by microglia, including scavenger receptors, Toll-like receptors, purinergic G protein-coupled receptors (P2Y2 and P2Y6), TREM2, complement components and their associated receptors (Brazil et al., 2000; Choucair-Jaafar et al., 2011; El Khoury e…”
BackgroundGenetic Variability in Molecular Pathways Implicated in Alzheimer's Disease: A Comprehensive Review
Vogrinc, D., Goričar, K., & Dolžan, V. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.646901 · Cited by 36
“Complement inhibition can reduce the clearance of Aβ in animal models (Wyss-Coray et al., 2002).”
BackgroundGroen, T. V., Liu, L., Ikonen, S., & Kadish, I. (2003) · Neuroscience · doi:10.1016/s0306-4522(03)00215-x · Cited by 41
Depboylu, C., Schäfer, M., Schwaeble, W., Reinhart, T. A., MAEDA, H., Mitsuya, H., Damadzic, R., Rausch, D. M., Eiden, L. E., & Weihe, E. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.01.030 · Cited by 34
“On the other hand, complement activation can reduce neurodegeneration and plaque formation in a mouse model of Alzheimer’s disease (Wyss-Coray et al., 2002).”
BackgroundLettiero, B., Andersen, A. J., Hunter, A. C., & Moghimi, S. M. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.10.036 · Cited by 35
“However, a C3-mediated protective role has been observed in AD mouse models where C3 is deficient or inhibited by the overexpression of soluble complement receptor-related protein y (sCrry) [54,55].”
Membrane Protein Crry Maintains Homeostasis of the Complement System
Wu, X., Spitzer, D., Mao, D., Peng, S. L., Molina, H. D., & Atkinson, J. P. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.4.2732 · Cited by 34
“For example, Crry plays a role in the pathogenesis of autoimmune disorders (such as MRL/lpr mice) (49, 50), ischemia/reperfusion injury (51), and Alzheimer’s disease (52, 53).”
BackgroundNeutrophil to lymphocyte ratio in Alzheimer’s disease: A systematic review and meta-analysis
Mohammadi, A., Mohammadi, M., Almasi‐Dooghaee, M., & Mirmosayyeb, O. (2024) · PLoS ONE · doi:10.1371/journal.pone.0305322 · Cited by 40
“However, prolonged inflammation leads to a loss of the microglial cells’ ability to clear these plaques [8, 32, 33].”
BackgroundHow the gut microbiota impacts neurodegenerative diseases by modulating CNS immune cells
Schaible, P., Henschel, J., & Erny, D. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03371-0 · Cited by 35
“This chronic immune activation can lead to an exhausted microglial state and downregulation of Aβ-degrading enzymes such as insulin-degrading enzyme (IDE) and neprilysin (NEP) (Wyss-Coray et al. 2002).”
Shinjyo, N., Kagaya, W., & Pekna, M. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.710390 · Cited by 34
Alzheimer’s Disease Treatment: The Search for a Breakthrough
Reiss, A. B., Muhieddine, D., Jacob, B., Mesbah, M., Pinkhasov, A., Gomolin, I. H., Stecker, M. M., Wısnıewskı, T., & Leon, J. D. (2023) · Medicina · doi:10.3390/medicina59061084 · Cited by 37
The Double-Edged Flower: Roles of Complement Protein C1q in Neurodegenerative Diseases
Tenner, A. J., & Fonseca, M. I. (2007) · Springer eBooks · doi:10.1007/0-387-34134-x_11 · Cited by 34
CR1, ABCA7, and APOE genes affect the features of cognitive impairment in Alzheimer's disease
Chung, S. J., Kim, M., Kim, Y. J., Kim, J., You, S., Jang, E. H., Kim, S. Y., & Lee, J. (2014) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2014.01.029 · Cited by 36
Toledo, J. B., Korff, A., Shaw, L. M. J., Trojanowski, J. Q., Zhang, J., & Initiative, T. A. D. N. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt266 · Cited by 34
“To this end, many studies have indicated potential involvement of complement system in AD pathogenesis, including observations that: Aβ fibrils activate both the classical and alternative complement pathways in vitro [44-46]; inhibition of C3 in a mouse model of AD resulted in accelerated and increased Aβ plaque depos…”
Cytokines in CNS Inflammation and Disease
Tansey, M. G., & Wyss‐Coray, T. (2007) · Springer eBooks · doi:10.1007/978-0-387-73894-9_5 · Cited by 37
Self-citationGhanbari, M., Munshi, S. T., Ma, B., Lendemeijer, B., Bansal, S., Adams, H. H. H., Wang, W., Goth, K., Slump, D. E., van den Hout, M. C. G. N., et al. (2019) · Human Mutation · doi:10.1002/humu.23872 · Cited by 33
Precision Medicine in Neurology: The Inspirational Paradigm of Complement Therapeutics
Gavriilaki, M., Kimiskidis, V. Κ., & Gavriilaki, E. (2020) · Pharmaceuticals · doi:10.3390/ph13110341 · Cited by 33
Gatta, V., Drago, D., Fincati, K., Valenti, M. T., Carbonare, L. D., Sensi, S. L., & Zatta, P. F. (2011) · PLoS ONE · doi:10.1371/journal.pone.0015965 · Cited by 36
“TGFB1 encodes for the Golgi-specific brefeldin A-resistance guanine nucleotide exchange factor 1 protein that forms a heteromeric complex with the TGF-beta receptors type II and participates in the transforming growth factor (TGF)-1 signaling cascade. TGF Beta -1 can have a role in AD as experiments in AD transgenic m…”
BackgroundRegulatory function of glycosphingolipids in the inflammation and degeneration
Furukawa, K., Ohmi, Y., Kondo, Y., Ohkawa, Y., Tajima, O., & Furukawa, K. (2015) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2015.02.007 · Cited by 33
Sherva, R., & Farrer, L. A. (2011) · Current Psychiatry Reports · doi:10.1007/s11920-011-0184-4 · Cited by 33
“The evidence for this comes from a murine model in which overexpression of C3 in transgenic mice resulted in lower Aβ deposition and neurodegeneration was observed in the C3 knockdown mice [ 44 ].”
BackgroundMicroglial carbohydrate-binding receptors for neural repair
Linnartz‐Gerlach, B., Bodea, L., & Neumann, H. (2012) · Cell and Tissue Research · doi:10.1007/s00441-012-1342-7 · Cited by 32
“A blocking of the complement activation reduces the activation of microglia in a mouse model of AD resulting in an increased amyloid load (Wyss-Coray et al. 2002).”
BackgroundAutophagy is involved in oral rAAV/Aβ vaccine-induced Aβ clearance in APP/PS1 transgenic mice
Wang, H.-C., Zhang, T., Kuerban, B., Jin, Y.-L., Le, W., Hara, H., Fan, D.-S., Wang, Y., Tabira, T., & Chui, D.-H. (2015) · Neuroscience Bulletin · doi:10.1007/s12264-015-1546-4 · Cited by 30
Lee, M., Guo, J., Schwab, C., McGeer, E. G., & McGeer, P. L. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.12.005 · Cited by 33
“In these ouble transgenic mice at 1 year of age, deposition of myloid-beta protein was 3-fold higher than in the hAPP ice (Wyss-Coray et al., 2002).”
BackgroundGe, T.-Q., Guan, P.-P., & Wang, P. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105868 · Cited by 29
Metadata
- Authors
- Wyss-Coray, T., Yan, F., Lin, A. H.-T., Lambris, J. D., Alexander, J. J., Quigg, R. J., & Masliah, E.
- Affiliations
- Gladstone Institute of Neurological Disease and Department of Neurology, University of California, San Francisco, CA 94141; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104; Department of Medicine, Section of Nephrology, University of Chicago, Chicago, IL 60637; and Departments of Neurosciences and Pathology, University of California at San Diego, La Jolla, CA 92093
- University of California, San Francisco (US)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2002-07-15
- Volume
- 99
- Issue
- 16
- Pages
- 10837-10842
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC125059
- OpenAlex
- W2047658053
- Cited by
- 446
- References
- 47
- Citations by year
- 2026: 4 · 2025: 13 · 2024: 18 · 2023: 10 · 2022: 13 · 2021: 19 · 2020: 24 · 2019: 21 · 2018: 16 · 2017: 11 · 2016: 13 · 2015: 18 · 2014: 20 · 2013: 17 · 2012: 28
- FWCI
- 9.61
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (1r01ag015871-01a1, AG5131, n01ai30040-13-0-5, 5r29ag010869-05, AI-30040, AG10869, AG15871)
- National Institute on Aging (P50AG005131, AG-5131, AG10869, AG15871)
- National Institute of Allergy and Infectious Diseases (AI30040, N01 AI030040)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK41873, DK58820, R56DK041873, R01DK041873, U24DK058820)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Keywords
- Alzheimer's disease, complement activation, complement C3, amyloid-beta deposition, amyloid plaques, neurodegeneration, TGF-β1, microglial activation, innate immunity, amyloid precursor protein transgenic mice, neuroinflammation, amyloid clearance
- MeSH terms
- Alzheimer Disease, Animals, Brain, Complement Activation, Complement C3, Disease Models, Animal, Humans, Mice, Inbred C57BL, Mice, Transgenic, Nerve Degeneration, Neurons, Receptors, Complement, Gene Expression, Amyloid beta-Protein Precursor, Receptors, Complement 3b, Mice, Knockout, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.